Conditioned medium from amniotic membrane-derived cells prevents lung fibrosis and preserves blood gas exchanges in bleomycin-injured mice-specificity of the effects and insights into possible mechanisms

Cytotherapy

Volumn 16, Issue 1, 2014, Pages 17-32

  Cargnoni, Anna ^a   Piccinelli, Ester Cotti ^a   Ressel, Lorenzo ^a,b   Rossi, Daniele ^a   Magatti, Marta ^a   Toschi, Ivan ^c   Cesari, Valentina ^c   Albertini, Mariangela ^c   Mazzola, Silvia ^c   Parolini, Ornella ^a  

^a Fondazione Poliambulanza Istituto Ospedaliero   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Amniotic membrane derived cells; Amniotic mesenchymal tissue cells; Conditioned medium; Human term placenta; Lung fibrosis; Mesenchymal stromal cell

Indexed keywords

COLLAGEN; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AMNION CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL GAS; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GAS EXCHANGE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL LINE; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; LUNG INJURY; LUNG PARENCHYMA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; SKIN FIBROBLAST; SURVIVAL RATE; T LYMPHOCYTE; WEIGHT CHANGE;

MUS;

AMNIOTIC MEMBRANE-DERIVED CELLS; AMNIOTIC MESENCHYMAL TISSUE CELLS; CONDITIONED MEDIUM; HUMAN TERM PLACENTA; LUNG FIBROSIS; MESENCHYMAL STROMAL CELL;

AMNION; ANIMALS; BLEOMYCIN; BLOOD GAS ANALYSIS; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; HUMANS; LUNG; MICE; PULMONARY FIBROSIS;

EID: 84890983425     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.07.002     Document Type: Article

References (58)

1. Bailo M., Soncini M., Vertua E., Signoroni P.B., Sanzone S., Lombardi G., et al. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation 2004, 78:1439-1448.
2. Wolbank S., Peterbauer A., Fahrner M., Hennerbichler S., van Griensven M., Stadler G., et al. Dose-dependent immunomodulatory effect of human stem cells from amniotic membrane: a comparison with human mesenchymal stem cells from adipose tissue. Tissue Eng 2007, 13:1173-1183.
3. Magatti M., De Munari S., Vertua E., Gibelli L., Wengler G.S., Parolini O. Human amnion mesenchyme harbors cells with allogeneic T-cell suppression and stimulation capabilities. Stem Cells 2008, 26:182-192.
4. Magatti M., De Munari S., Vertua E., Nassauto C., Albertini A., Wengler G.S., et al. Amniotic mesenchymal tissue cells inhibit dendritic cell differentiation of peripheral blood and amnion resident monocytes. Cell Transplant 2009, 18:899-914.
5. Parolini O., Alviano F., Bergwerf I., Boraschi D., De Bari C., De Waele P., et al. Toward cell therapy using placenta-derived cells: disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev 2010, 19:143-154.
6. Parolini O., Caruso M. Review: preclinical studies on placenta-derived cells and amniotic membrane: an update. Placenta 2011, 32(Suppl 2):S186-S195.
7. Manuelpillai U., Moodley Y., Borlongan C.V., Parolini O. Amniotic membrane and amniotic cells: potential therapeutic tools to combat tissue inflammation and fibrosis?. Placenta 2011, 32(Suppl 4):S320-S325.
8. Cargnoni A., Gibelli L., Tosini A., Signoroni P.B., Nassuato C., Arienti D., et al. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycin-induced lung fibrosis. Cell Transplant 2009, 18:405-422.
9. Moodley Y., Ilancheran S., Samuel C., Vaghjiani V., Atienza D., Williams E.D., et al. Human amnion epithelial cell transplantation abrogates lung fibrosis and augments repair. Am J Respir Crit Care Med 2010, 182:643-651.
10. Murphy S., Lim R., Dickinson H., Acharya R., Rosli S., Jenkin G., et al. Human amnion epithelial cells prevent bleomycin-induced lung injury and preserve lung function. Cell Transplant 2011, 20:909-923.
11. Vosdoganes P., Hodges R.J., Lim R., Westover A.J., Acharya R.Y., Wallace E.M., et al. Human amnion epithelial cells as a treatment for inflammation-induced fetal lung injury in sheep. Am J Obstet Gynecol 2011, 205(156):e26-e33.
12. Cargnoni A., Ressel L., Rossi D., Poli A., Arienti D., Lombardi G., et al. Conditioned medium from amniotic mesenchymal tissue cells reduces progression of bleomycin-induced lung fibrosis. Cytotherapy 2012, 14:153-161.
13. Soncini M., Vertua E., Gibelli L., Zorzi F., Denegri M., Albertini A., et al. Isolation and characterization of mesenchymal cells from human fetal membranes. JTissue Eng Regen Med 2007, 1:296-305.
14. Rossi D., Pianta S., Magatti M., Sedlmayr P., Parolini O. Characterization of the conditioned medium from amniotic membrane cells: prostaglandins as key effectors of its immunomodulatory activity. PLoS One 2012, 7:e46956.
15. Magatti M., De Munari S., Vertua E., Parolini O. Amniotic membrane-derived cells inhibit proliferation of cancer cell lines by inducing cell cycle arrest. JCell Mol Med 2012, 16:2208-2218.
16. Gharaee-Kermani M., Hatano K., Nozaki Y., Phan S.H. Gender-based differences in bleomycin-induced pulmonary fibrosis. Am J Pathol 2005, 166:1593-1606.
17. Ashcroft T., Simpson J.M., Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. JClin Pathol 1988, 41:467-470.
18. Degryse A.L., Tanjore H., Xu X.C., Polosukhin V.V., Jones B.R., Boomershine C.S., et al. TGFbeta signaling in lung epithelium regulates bleomycin-induced alveolar injury and fibroblast recruitment. Am J Physiol Lung Cell Mol Physiol 2011, 300:L887-L897.
19. Zhu Y., Liu Y., Zhou W., Xiang R., Jiang L., Huang K., et al. Aprostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice. Respir Res 2010, 11:34.
20. Genovese T., Cuzzocrea S., Di Paola R., Mazzon E., Mastruzzo C., Catalano P., et al. Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005, 25:225-234.
21. Wilborn J., Crofford L.J., Burdick M.D., Kunkel S.L., Strieter R.M., Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. JClin Invest 1995, 95:1861-1868.
22. Zhou A., Guo L., Tang L. Effect of an intrathoracic injection of sodium hyaluronic acid on the prevention of pleural thickening in excess fluid of tuberculous thoracic cavity. Clin Exp Pharmacol Physiol 2003, 30:203-205.
23. Mitamura T., Hosaka M., Takeda M., Watari H., Sakuragi N. Intrathoracic injection of paclitaxel for a patient with stage IV serous ovarian cancer: a case report. Cancer Chemother Pharmacol 2009, 64:169-170.
24. Chang C.C., Chuang S.T., Huang M.C. Effects of chronic treatment with various neuromuscular blocking agents on the number and distribution of acetylcholine receptors in the rat diaphragm. JPhysiol 1975, 250:161-173.
25. Kennedy M.T., Higgins B.D., Costello J.F., Curtin W.A., Laffey J.G. Hypertonic saline reduces inflammation and enhances the resolution of oleic acid induced acute lung injury. BMC Pulm Med 2008, 8:9.
26. Wynn T.A. Integrating mechanisms of pulmonary fibrosis. JExp Med 2011, 208:1339-1350.
27. Todd N.W., Luzina I.G., Atamas S.P. Molecular and cellular mechanisms of pulmonary fibrosis. Fibrogenesis Tissue Repair 2012, 5:11.
28. Smith R.E., Strieter R.M., Phan S.H., Lukacs N., Kunkel S.L. TNF and IL-6 mediate MIP-1alpha expression in bleomycin-induced lung injury. JLeukoc Biol 1998, 64:528-536.
29. Smith R.E., Strieter R.M., Phan S.H., Lukacs N.W., Huffnagle G.B., Wilke C.A., et al. Production and function of murine macrophage inflammatory protein-1 alpha in bleomycin-induced lung injury. JImmunol 1994, 153:4704-4712.
30. Zhang K., Gharaee-Kermani M., Jones M.L., Warren J.S., Phan S.H. Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis. JImmunol 1994, 153:4733-4741.
31. Inoshima I., Kuwano K., Hamada N., Hagimoto N., Yoshimi M., Maeyama T., et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2004, 286:L1038-L1044.
32. Chaudhary N.I., Schnapp A., Park J.E. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006, 173:769-776.
33. Wilson M.S., Wynn T.A. Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol 2009, 2:103-121.
34. Kottmann R.M., Hogan C.M., Phipps R.P., Sime P.J. Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology 2009, 14:917-933.
35. Misharin A.V., Scott Budinger G.R., Perlman H. The lung macrophage: a Jack of all trades. Am J Respir Crit Care Med 2011, 184:497-498.
36. Gibbons M.A., MacKinnon A.C., Ramachandran P., Dhaliwal K., Duffin R., Phythian-Adams A.T., et al. Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis. Am J Respir Crit Care Med 2011, 184:569-581.
37. Wynn T.A., Ramalingam T.R. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature Med 2012, 18:1028-1040.
38. Boorsma C.E., Draijer C., Melgert B.N. Macrophage heterogeneity in respiratory diseases. Mediators Inflamm 2013, 2013. Available at:. http://www.hindawi.com/journals/mi/2013/769214/cta/.
39. Khalil N., Bereznay O., Sporn M., Greenberg A.H. Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. JExp Med 1989, 170:727-737.
40. Murray L.A., Rosada R., Moreira A.P., Joshi A., Kramer M.S., Hesson D.P., et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS One 2010, 5:e9683.
41. Murray P.J., Wynn T.A. Protective and pathogenic functions of macrophage subsets. Nat Rev 2011, 11:723-737.
42. Haniffa M.A., Collin M.P., Buckley C.D., Dazzi F. Mesenchymal stem cells: the fibroblasts' new clothes?. Haematologica 2009, 94:258-263.
43. Cappellesso-Fleury S., Puissant-Lubrano B., Apoil P.A., Titeux M., Winterton P., Casteilla L., et al. Human fibroblasts share immunosuppressive properties with bone marrow mesenchymal stem cells. JClin Immunol 2010, 30:607-619.
44. Donnelly J.J., Xi M.S., Rockey J.H. Asoluble product of human corneal fibroblasts inhibits lymphocyte activation: enhancement by interferon-gamma. Exp Eye Res 1993, 56:157-165.
45. Moodley Y.P., Scaffidi A.K., Misso N.L., Keerthisingam C., McAnulty R.J., Laurent G.J., et al. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am J Pathol 2003, 163:345-354.
46. Gharaee-Kermani M., Denholm E.M., Phan S.H. Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors. JBiol Chem 1996, 271:17779-17784.
47. Saito F., Tasaka S., Inoue K., Miyamoto K., Nakano Y., Ogawa Y., et al. Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol 2008, 38:566-571.
48. Moore B.B., Paine R., Christensen P.J., Moore T.A., Sitterding S., Ngan R., et al. Protection from pulmonary fibrosis in the absence of CCR2 signaling. JImmunol 2001, 167:4368-4377.
49. Keerthisingam C.B., Jenkins R.G., Harrison N.K., Hernandez-Rodriguez N.A., Booth H., Laurent G.J., et al. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response totransforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001, 158:1411-1422.
50. Failla M., Genovese T., Mazzon E., Fruciano M., Fagone E., Gili E., et al. 16,16-Dimethyl prostaglandin E2 efficacy on prevention and protection from bleomycin-induced lung injury and fibrosis. Am J Respir Cell Mol Biol 2009, 41:50-58.
51. Moore B.B., Coffey M.J., Christensen P., Sitterding S., Ngan R., Wilke C.A., et al. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. JImmunol 2000, 165:4032-4039.
52. Moore B.B., Ballinger M.N., White E.S., Green M.E., Herrygers A.B., Wilke C.A., et al. Bleomycin-induced E prostanoid receptor changes alter fibroblast responses to prostaglandin E2. JImmunol 2005, 174:5644-5649.
53. Steed D.L., Trumpower C., Duffy D., Smith C., Marshall V., Rupp R., et al. Amnion-derived cellular cytokine solution: a physiological combination of cytokines for wound healing. Eplasty 2008, 8:e18.
54. Wolbank S., Hildner F., Redl H., van Griensven M., Gabriel C., Hennerbichler S. Impact of human amniotic membrane preparation on release of angiogenic factors. JTissue Eng Regen Med 2009, 3:651-654.
55. Li H, Niederkorn JY, Neelam S, Mayhew E, Word RA, McCulley JP, etal. Immunosuppressive factors secreted by human amniotic epithelial cells. Invest Ophthalmol Vis Sci. 2005;46:900-907.
56. Denison F.C., Kelly R.W., Calder A.A., Riley S.C. Cytokine secretion by human fetal membranes, decidua and placenta at term. Hum Reprod 1998, 13:3560-3565.
57. Burchfield J.S., Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008, 1:4.
58. Boomsma R.A., Geenen D.L. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PLoS One 2012, 7:e35685.